Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation
Phase 4
- Conditions
- Arteriovenous Malformations
- Interventions
- Drug: MedroxyPROGESTERone Injection [Depo-Provera]Device: Other
- Registration Number
- NCT05491343
- Lead Sponsor
- HaEmek Medical Center, Israel
- Brief Summary
A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 28
Inclusion Criteria
- women between age of 18 to 50, diagnosed with AVM
- hemodynamically stable at clinical presentation
Exclusion Criteria
- unstable patients
- contraindication to treatment
- US examination not in the US department
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Progesterone treatment MedroxyPROGESTERone Injection [Depo-Provera] - Progesterone treatment Other -
- Primary Outcome Measures
Name Time Method AVM regression 3 weeks The time from diagnosis to regression
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie progesterone's effect on uterine arteriovenous malformations?
How does Medroxyprogesterone compare to standard-of-care embolization for uterine AVM management?
Are there specific biomarkers that predict response to progesterone treatment in uterine AVMs?
What are the potential adverse events associated with Medroxyprogesterone injection for AVM therapy?
What combination therapies are being explored alongside progesterone for uterine vascular anomalies?